This year’s Global Virtual Sarcoidosis Summit, hosted by the Foundation for Sarcoidosis Research (FSR), is bringing together the sarcoidosis community under the theme “Find Your Community, Find Your Life.” Those interested in taking part in the summit, happening virtually from Nov. 3 to 5, can register…
News
The Ann Theodore Foundation and the Milken Institute are once again teaming up to offer grants worth up to $3.4 million to help spur research into sarcoidosis. “Varied perspectives and expertise are key to achieving progress in sarcoidosis research, which will then lead to better treatment,” Lisa…
Higher doses of the investigational therapy efzofitimod significantly reduced relapse rates after a dose of a corticosteroid was reduced in people with pulmonary sarcoidosis, according to a new, pooled analysis of Phase 1b/2a trial data. The first-in-class immunomodulatory therapy, developed by aTyr Pharma, also significantly improved lung…
Treatment with tumor necrosis factor-alpha (TNF-a) inhibitors — which block a type of immune protein in the body — was found to ease signs of inflammation and reduce the need for corticosteroids in people with cardiac sarcoidosis in a new analysis. Safety data, meanwhile, indicated that such treatments were…
Most cardiac sarcoidosis patients respond to six months of first-line treatment with the corticosteroid prednisolone and show reduced active inflammation in the heart, according to a small study in Japan. Cardiovascular events were less common among responders relative to those who respondly poorly, further confirming first-line prednisolone’s effectiveness…
Top-line data from an ongoing Phase 2 trial testing Kinevant Sciences’ experimental therapy namilumab in adults with pulmonary sarcoidosis are expected in the second half of 2024. That’s according to a business update from Roivant Sciences, the parent company to Kinevant. Called RESOLVE-Lung (NCT05314517), the…
MRI scans of the heart may help in predicting the risk of cardiac sarcoidosis recurring after initial successful treatment, a study reports. A greater extent of scarred heart tissue prior to treatment, in particular, was associated with a five times higher risk of relapse. The presence of sarcoidosis only…
Death rates while waiting for a lung transplant are disproportionally higher among people with pulmonary sarcoidosis than for those with other lung disorders, a U.S. study shows. “Our research shows that further consideration needs to be given to how we classify patients with sarcoidosis and how we calculate their…
The Foundation for Sarcoidosis Research (FSR) is funding a new research project that aims to find biological markers that could help identify people with sarcoidosis who are at risk of developing advanced lung disease. The work will be led by Christen Vagts, MD, an early career physician scientist…
The U.S. Food and Drug Administration (FDA) has greenlit a month-old request by Molecure to begin a Phase 2 clinical trial of its investigational oral therapy OATD-01 in people with pulmonary sarcoidosis. The proof-of-concept study, which is ready to launch, according to Molecure, will be the first…
Recent Posts
- New report highlights unmet needs and treatment burdens in sarcoidosis
- Cardiac sarcoidosis symptoms at diagnosis help predict long-term risk
- Methotrexate is safer second-line sarcoidosis treatment than MMF
- A holiday gift guide for your loved one with sarcoidosis
- FSR gathers global leaders to drive progress in sarcoidosis research
- New genetic clues connect sarcoidosis with lung cancer risk
- When patients and caregivers swap roles, empathy usually follows
- Underdiagnosis of cardiac sarcoidosis leaves people at risk
- Repurposing drugs may improve survival for people with sarcoidosis
- Few with sarcoidosis see lung specialist within a year of diagnosis